Esperance Pharmaceuticals (Esperance)

Oncology Corporate Profile

HQ Location

340 East Parker Blvd.
Baton Rouge, LA 70803

Company Description

Esperance is developing unique and innovative targeted cancer drugs, called membrane disrupting peptides (MDPs) that utilize a novel mechanism of action to selectively kill cancer cells. These drugs kill only cancer cells that express the target molecules without harming normal cells. Esperance's drugs kill cancer cells that are known to be resistant to traditional chemotherapeutic drugs.

Website: http://www.esperancepharma.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
EP-100membrane-disrupting peptide (MDP)Ovarian cancerII
EP-100membrane-disrupting peptide (MDP)Breast cancerI
EP-100membrane-disrupting peptide (MDP)Endometrial cancerI
EP-100membrane-disrupting peptide (MDP)Neuroendocrine tumorI
EP-100membrane-disrupting peptide (MDP)Pancreatic cancerI
EP-100membrane-disrupting peptide (MDP)Prostate cancerI
EP-200membrane-disrupting peptide (MDP)Breast cancerPreclinical
EP-200membrane-disrupting peptide (MDP)Endometrial cancerPreclinical
EP-200membrane-disrupting peptide (MDP)Ovarian cancerPreclinical
EP-200membrane-disrupting peptide (MDP)Prostate cancerPreclinical
EP-400antibody drug conjugateVarious cancer typesPreclinical
EP-300membrane-disrupting peptide (MDP)Various cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.esperancepharma.com

Recent News Headlines

Esperance Announces Strategic Alliance with MD Anderson Cancer Center

8/25/2015 04:48 pm

(SYS-CON Media) Aug 24, 2015 - Esperance and MD Anderson will collaborate to accelerate development of EP-100 in ovarian and breast cancer.

Clinical Trial Begins in Boston for MRI-Compatible Robot

9/22/2014 06:05 am

(Worcester Polytechnic Institute [Worcester, MA]) Sept 18, 2014 - Developed by researchers at WPI, Johns Hopkins, and Brigham and Women's Hospital, the robotic system, designed to improve prostate cancer biopsies, is being tested as part of a larger clinical trial at BWH.

Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer

8/28/2012 04:30 pm

(TucsonNewsNow.com) Aug 28, 2012 - Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP 100 in combination with paclitaxel for patients with advanced ovarian cancer.

Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer

8/28/2012 11:03 am

(TucsonNewsNow.com) Aug 28, 2012 - Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP 100 in combination with paclitaxel for patients with advanced ovarian cancer.

Esperance Pharmaceuticals Initiates Phase 2 Clinical Trial of Its Novel Membrane-disrupting Agent, EP-100, in Patients With Advanced Ovarian Cancer

5/18/2012 04:48 pm

(Yahoo! Finance) May 17, 2012 - Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer.

Esperance Pharmaceuticals Initiates Phase 2 Clinical Trial of Its Novel Membrane-disrupting Agent, EP-100, in Patients With Advanced Ovarian Cancer

5/18/2012 11:04 am

(Yahoo! Finance) May 17, 2012 - Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer.

Argos Therapeutics' Arcelis Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes

6/1/2011 11:05 am

(Yahoo! Finance) June 1, 2011 - Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes.

Senate Republicans Push to Oust Medicare Chief

3/4/2011 11:03 am

(Washington Post) Mar 3, 2011 - Unable to repeal President Barack Obama's health care law, Republicans are trying to oust the official who is quarterbacking the overhaul of the nation's medical system.